A panel of advisers to the Food and Drug Administration met Tuesday to consider whether use of Moderna Inc.’s Covid-19 vaccine should be expanded to include children ages 6 through 17.
The advisory committee is expected to vote Tuesday afternoon on whether the benefits of vaccinating children in this age group outweigh the risks. The FDA will consider the vote in making a final decision on whether to clear the vaccine for use in children 6 years and older.
